366 related articles for article (PubMed ID: 27881144)
1. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.
Horneff G; Klein A; Klotsche J; Minden K; Huppertz HI; Weller-Heinemann F; Kuemmerle-Deschner J; Haas JP; Hospach A
Arthritis Res Ther; 2016 Nov; 18(1):272. PubMed ID: 27881144
[TBL] [Abstract][Full Text] [Related]
2. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
[TBL] [Abstract][Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
Windschall D; Horneff G
Clin Rheumatol; 2016 Dec; 35(12):2925-2931. PubMed ID: 27709443
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry.
Klein A; Becker I; Minden K; Foeldvari I; Haas JP; Horneff G
Scand J Rheumatol; 2019 Mar; 48(2):95-104. PubMed ID: 30411654
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry.
Armaroli G; Klein A; Ganser G; Ruehlmann MJ; Dressler F; Hospach A; Minden K; Trauzeddel R; Foeldvari I; Kuemmerle-Deschner J; Weller-Heinemann F; Urban A; Horneff G
Arthritis Res Ther; 2020 Oct; 22(1):258. PubMed ID: 33121528
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis.
Grönlund MM; Remes-Pakarinen T; Kröger L; Markula-Patjas K; Backström M; Putto-Laurila A; Aalto K; Vähäsalo P
Rheumatology (Oxford); 2020 Apr; 59(4):732-741. PubMed ID: 31359057
[TBL] [Abstract][Full Text] [Related]
9. Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry.
Klein A; Klotsche J; Hügle B; Minden K; Hospach A; Weller-Heinemann F; Schwarz T; Dressler F; Trauzeddel R; Hufnagel M; Foeldvari I; Borte M; Kuemmerle-Deschner J; Brunner J; Oommen PT; Föll D; Tenbrock K; Urban A; Horneff G
Rheumatology (Oxford); 2020 Sep; 59(9):2287-2298. PubMed ID: 31846042
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review.
Davies R; Gaynor D; Hyrich KL; Pain CE
Semin Arthritis Rheum; 2017 Apr; 46(5):584-593. PubMed ID: 27914689
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
[TBL] [Abstract][Full Text] [Related]
12. Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry.
Raab A; Kallinich T; Huscher D; Foeldvari I; Weller-Heinemann F; Dressler F; Kuemmerle-Deschner JB; Klein A; Horneff G
Pediatr Rheumatol Online J; 2021 Mar; 19(1):41. PubMed ID: 33752685
[TBL] [Abstract][Full Text] [Related]
13. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
Foeldvari I; Becker I; Horneff G
Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
[TBL] [Abstract][Full Text] [Related]
14. Biologics with or without methotrexate in treatment of polyarticular juvenile idiopathic arthritis: effectiveness, safety and drug survival.
Thiele F; Klein A; Klotsche J; Windschall D; Dressler F; Kuemmerle-Deschner J; Minden K; Foeldvari I; Foell D; Mrusek S; Oommen PT; Horneff G
Rheumatology (Oxford); 2023 Jun; 62(6):2230-2238. PubMed ID: 36222562
[TBL] [Abstract][Full Text] [Related]
15. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.
Jørgensen TS; Kristensen LE; Christensen R; Bliddal H; Lorenzen T; Hansen MS; Østergaard M; Jensen J; Zanjani L; Laursen T; Butt S; Dam MY; Lindegaard HM; Espesen J; Hendricks O; Kumar P; Kincses A; Larsen LH; Andersen M; Næser EK; Jensen DV; Grydehøj J; Unger B; Dufour N; Sørensen V; Vildhøj S; Hansen IM; Raun J; Krogh NS; Hetland ML
Rheumatology (Oxford); 2015 Dec; 54(12):2156-65. PubMed ID: 26175471
[TBL] [Abstract][Full Text] [Related]
17. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?
Anink J; Otten MH; Gorter SL; Prince FH; van Rossum MA; van den Berg JM; van Pelt PA; Kamphuis S; Brinkman DM; Swen WA; Swart JF; Wulffraat NM; Dolman KM; Koopman-Keemink Y; Hoppenreijs EP; Armbrust W; ten Cate R; van Suijlekom-Smit LW
Rheumatology (Oxford); 2013 Sep; 52(9):1674-9. PubMed ID: 23740187
[TBL] [Abstract][Full Text] [Related]
18. The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy.
Boqaeid A; Layqah L; Alonazy A; Althobaiti M; Almahlawi AZ; Al-Roqy A; Baharoon O; Alsaeedi A; Shamou J; Baharoon S
J Infect Public Health; 2024 Jun; 17(6):1134-1141. PubMed ID: 38728834
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
Brunner HI; Ruperto N; Zuber Z; Cuttica R; Keltsev V; Xavier RM; Burgos-Vargas R; Penades IC; Silverman ED; Espada G; Zavaler MF; Kimura Y; Duarte C; Job-Deslandre C; Joos R; Douglass W; Wimalasundera S; Bharucha KN; Wells C; Lovell DJ; Martini A; de Benedetti F;
Arthritis Rheumatol; 2021 Mar; 73(3):530-541. PubMed ID: 32951358
[TBL] [Abstract][Full Text] [Related]
20. Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry.
Becker I; Horneff G
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):552-560. PubMed ID: 27390133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]